We are a leading European venture capital firm. Our international team is driven by science, with the ambition to transform capital into medical breakthroughs.
At Ysios Capital, the management team and strength
of science of each venture are key to our investment thesis.
We invest in companies bringing life-changing treatments to patients, with a focus on indications with high unmet need.
medical products brought from
lab to market
medical products at clinical
stage for serious diseases
collaborations with leading
We invest globally in biotech ventures, focusing exclusively on innovative therapeutic drugs.
We seek exceptional teams with pioneering science and the drive to change patients' lives.
Ysios Capital was founded in 2008 and has offices in San Sebastian and Barcelona. We are the largest life sciences venture capital firm in Spain, with our investment successes providing a significant boost to the country’s biotech sector.
Since our inception, we have grown rapidly to become a leading global investment firm.
We manage over €400M ($500M ) in assets
across three global funds
Investing in asset-centric companies and product-enabling platform technologies with proprietary products.
CytoKi Pharma is a biotechnology company engaged in the development of protein drugs for diseases characterized by epithelial injury, with focus on developing a licensed long-acting IL-22 program for Inflammatory Bowel Disease and potentially additional clinical indications.
Adcendo aps is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (adcs).
Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS)
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases.
LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases.
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, founded in 2016, that is specialized in the discovery and development of therapeutic proteins for the prevention and treatment of bleeding. The company’s leading product in development, VMX-C001, is a new therapeutic protein to prevent or stop severe bleeding in patients taking blood thinners in the form of direct factor Xa inhibitors.